Project Grant R21CA297690
Award Date 9/5/25
Completion Date 8/31/27
Dollars Obligated $411K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...
- The National Cancer Institute awarded a $269,280 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Cold Spring Harbor Laboratory, a non-profit research institution. The grant supports the development of a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create prodrug molecules that can selectively degrade the K-RAS(G12C) protein and release cytotoxic polypharmaceuticals to concurrently target multiple pathways. The key...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- This $607,849 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research at Weill Medical College of Cornell University to investigate mechanisms of genetic and non-genetic resistance to KRAS inhibitor drugs for the treatment of lung and colorectal cancers. The research aims to define how cancer cells can develop resistance to KRAS-targeted therapies, including through inflammatory gene expression pathways. The project will...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to mechanistically understand and modulate cytoskeletal regulation as a way to overcome innate resistance to KRAS inhibition in cancer. The $375,150 award, with a performance period from September 1, 2025 to August 31, 2030, was made to the University of California, San Francisco (UCSF). The research aims to study adaptive resistance mechanisms, including the...
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
- The National Cancer Institute awarded a $406,500 Project Grant to Trethera Corp under the Cancer Treatment Research program (CFDA 93.395) to fund the development of a novel, targeted small molecule inhibitor called TRE-515. The goal is to establish the deoxycytidine kinase (DCK) enzyme as a targetable resistance mechanism for KRAS inhibitors in non-small-cell lung cancer (NSCLC) models. The research will evaluate the improved efficacy of KRAS inhibitors when combined with TRE-515 in KRAS-G12C...
- The University of Cincinnati was awarded a $162,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support research on "Targeting the HER Family in KRAS Mutant Colorectal Cancer". The grant aims to examine novel treatment strategies combining a KRAS inhibitor with a HER3 antibody-drug conjugate containing the payload exatecan. The 2-year project, running from July 1, 2025 to June 30, 2027, will explore how colorectal cancers with KRAS...
- This federal Project Grant award for $657,776.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), will support the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The University of Pittsburgh, as the awardee, will engineer the anthrax toxin protein delivery system and the DUF5 toxin effector domain to create a potent and tumor-selective RAS inactivator. This innovative approach aims to address the...
- The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, awarded a $188,351 Project Grant to The Ohio State University (OSU) to support research on identifying mutation-specific features, regulators, and combination therapy approaches for targeting KRAS oncoproteins in cancer. This 3-year grant will focus on studying the regulation of different KRAS mutations and evaluating the therapeutic potential of a novel pan-KRAS inhibitor discovered by the research...